Get the Stockscreener App
1.51
28.77%
-0.61
After Hours:
1.55
0.04
+2.65%
Pulmatrix Inc stock is traded at $1.51, with a volume of 807.26K.
It is down -28.77% in the last 24 hours and down -48.11% over the past month.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
See More
Previous Close:
$2.12
Open:
$1.56
24h Volume:
807.26K
Relative Volume:
17.93
Market Cap:
$5.51M
Revenue:
$3,000
Net Income/Loss:
$-5.16M
P/E Ratio:
-1.0684
EPS:
-1.4133
Net Cash Flow:
$-5.43M
1W Performance:
-29.77%
1M Performance:
-48.11%
6M Performance:
-65.91%
1Y Performance:
-77.56%
1-Day Range:
$1.41
$1.66
1-Week Range:
$1.41
$2.49
52-Week Range:
$1.41
$9.37
Pulmatrix Inc Stock (PULM) Company Profile
Name
Pulmatrix Inc
Sector
Industry
Phone
(888) 355-4440
Address
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
1.51 | 7.74M | 3,000 | -5.16M | -5.43M | -1.4133 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-18 | Initiated | H.C. Wainwright | Buy |
Pulmatrix Inc Stock (PULM) Latest News
Deal Watch: Pulmatrix Finds New Merger Partner In Eos Senolytix - Citeline News & Insights
Eos SENOLYTIX, Inc. agreed to acquire Pulmatrix, Inc. in a reverse merger transaction. - marketscreener.com
Pulmatrix: Merger With Eos SENOLYTIX To Advance Mitochondrial Therapies - Pulse 2.0
Pulmatrix To Merge with Eos SENOLYTIX - citybiz
If You Invested $1,000 in Pulmatrix (PULM) - Stock Titan
Pulmatrix (PULM) to Acquire Eos Senolytix in Strategic Merger - GuruFocus
Pulmatrix to acquire Eos SENOLYTIX in $19M anti-aging deal - Investing.com
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan - PR Newswire
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
Buyout Rumor: Can Pulmatrix Inc grow without dilution2026 Closing Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Pulmatrix (NASDAQ:PULM) Stock Crosses Above Fifty Day Moving Average – Here’s Why - Defense World
Aug Catalysts: What are the analyst revisions for Vroom IncIs Pulmatrix Inc stock a good investment in YEARTrade Exit Report & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Risk Off: What is the earnings history of Pulmatrix IncWeekly Stock Report & Weekly High Conviction Ideas - baoquankhu1.vn
Why Pulmatrix Inc. stock is a value investor pickJuly 2025 Price Swings & Daily Growth Stock Investment Tips - Naître et grandir
Surprises Report: Will Pulmatrix Inc benefit from rising consumer demandShare Buyback & Capital Efficient Trade Techniques - baoquankhu1.vn
Pulmatrix, Inc. (PULM) Competitors - Meyka
PULM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulmatrix Pursues New Reverse Merger After Cullgen Termination - The Globe and Mail
Pulmatrix merger with Cullgen terminated by Chinese firm - Investing.com
Behavioral Patterns of PULM and Institutional Flows - Stock Traders Daily
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Asianet Newsable
Pulmatrix and Cullgen Terminate Merger Agreement - Contract Pharma
Pulmatrix (PULM) Pursues New Merger Opportunities Post Agreement Termination - GuruFocus
Pulmatrix announces termination of prior planned merger and continues pursuit of alternative merger opportunities - marketscreener.com
Pulmatrix Announces Termination Of Prior Planned Merger And Continues Pursuit Of Alternative Merger Opportunities - TradingView
Pulmatrix-Cullgen Merger Agreement Terminated; No Fees Payable - TradingView
CSRC delays leave Pulmatrix merger dead, company hunts new deal - Stock Titan
Pulmatrix, Inc. SEC 10-K Report - TradingView
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PULM: Revenue fell to nil in 2025 as the company pivots to merger and asset monetization strategies - TradingView
Pulmatrix (NASDAQ: PULM) cuts 2025 loss to $5.2M as Cullgen merger awaits approvals - Stock Titan
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results - PR Newswire
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results | PULM Stock News - Longbridge
PULM PE Ratio & Valuation, Is PULM Overvalued - Intellectia AI
Why Pulmatrix Inc. stock is in analyst buy zone2025 Market Trends & Low Risk Entry Point Guides - mfd.ru
Update Report: Will Pulmatrix Inc benefit from seasonalityVolume Spike & Technical Buy Zone Confirmations - baoquankhu1.vn
(PULM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Earnings Report: What is the earnings history of Pulmatrix IncPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below 50 Day Moving Average – What’s Next? - Defense World
Will Pulmatrix Inc. stock gain from strong economy2025 Macro Impact & Safe Swing Trade Setup Alerts - mfd.ru
Is Pulmatrix Inc. stock a buy before product launchesPortfolio Profit Report & AI Driven Stock Movement Reports - mfd.ru
Pulmatrix Announces Third Quarter 2024 Financial Results and Pro - GuruFocus
Is Pulmatrix Inc. stock a defensive play in 2025Short Setup & Technical Pattern Alert System - mfd.ru
Can Pulmatrix Inc. deliver alphaJuly 2025 Volume & Weekly Return Optimization Plans - mfd.ru
Will Pulmatrix Inc. benefit from rising consumer demandJuly 2025 Reactions & Free Risk Controlled Daily Trade Plans - mfd.ru
How (PULM) Movements Inform Risk Allocation Models - Stock Traders Daily
Profit Review: Will Pulmatrix Inc benefit from rising consumer demandPortfolio Value Report & Low Risk Entry Point Guides - baoquankhu1.vn
Will Pulmatrix Inc benefit from rising consumer demandPortfolio Value Report & Low Risk Entry Point Guides - baoquankhu1.vn
Market Review: Will Pulmatrix Inc benefit from rising consumer demandPortfolio Performance Report & Weekly Return Optimization Plans - baoquankhu1.vn
Aug Intraday: Will Greif Inc stock benefit from M AMarket Trend Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Hedge Fund Bets: Should you avoid Personalis Inc stock right nowEarnings Risk Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Pulmatrix Inc Stock (PULM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):